Objectives: It is important to identify aspects of analgesic use that are associated with harm in chronic pain. Historically, the focus has been patterns of use (eg, overuse). This study evaluated another aspect of use-rather than evaluating how analgesics were being used, the primary interest was in why they were being used.
A nalgesic medications are frequently used to treat chronic pain. For example, Breivik et al's survey of pain in Europe 1 indicated that almost half of the 4839 individuals surveyed were taking "over the counter" analgesics and two thirds were taking prescription analgesics. Similar high levels of analgesic consumption have been reported across several other studies. [2] [3] [4] [5] [6] [7] The frequent use of analgesics for chronic pain treatment is not without controversy, particularly for medications that have potential for misuse or addiction or which can be used recreationally. Although opioids are the most common area of controversy at present, [8] [9] [10] [11] there are multiple analgesic classes which have potential for problematic use. 12, 13 These include muscle relaxants and tranquilizers, 14 as well as benzodiazepines, which may have an indirect analgesic effect via their anxiolytic properties. 15 Given the potential for harm present in some analgesics, it is important to identify consumption patterns that are predictive of problems. A common approach has been to identify so-called "aberrant behaviors," such as frequent overuse, deviations from prescribed instructions, the occurrence of lost or stolen prescriptions, simultaneous use of nonprescribed opioids or illicit substances, or evidence of intoxication. 16, 17 The evidence underpinning the accuracy of these approaches, however, suggests that they are not reliable in identifying opioid consumers that will go on to develop substance use problems. 9, 18, 19 Thus, there is a need to identify specific qualities of use patterns that better predict problems.
One option for further study involves an examination of the individual's purposes for analgesic use. In other words, it may be important to identify why individuals are using analgesics as some of these reasons may be reliably related to patient functioning. Consumption patterns that appear similar between different individuals, for instance, may have varying impacts on functioning and quality of life, depending on the specific outcomes that are being pursued.
There are a range of possible reasons for analgesic consumption that can be postulated. From a treatment provider perspective, for example, analgesics are primarily used to reduce pain and improve functioning. Therefore, it may be that patients taking analgesics for these intended purposes experience less pain intensity and pain-related distress, and are at decreased risk of problematic substance use. In addition, analgesics may be used for emotional modulation or for emotional numbing. They may be used primarily to achieve sedation. Clinical experience suggests that individuals may also use analgesics simply because they want to feel like they are doing something or that they have no other alternative. For example, in a recent trial examining the feasibility of opioid tapering, Sullivan et al 20 observed that many patients felt that opioids were their only pain management option. It is also possible that patients are taking analgesics simply because they were told to do so by prescribers. Empirical examination of the accuracy of these reasons, and their relations with functioning, may aid in understanding why analgesics are useful for some people and harmful for others.
The first purpose of the present study was to develop a pool of items related to reasons for analgesic consumption in individuals with chronic pain and then perform an exploratory factor analysis on these items to determine whether a robust and interpretable factor structure could be identified. Next, we planned to examine how the identified factors related to aspects of functioning, including pain intensity, pain-related distress, and depression, as well as risk of opioid and alcohol misuse. We planned to examine these relations in individuals who were taking any analgesic for chronic pain and also in the subset of individuals taking opioids specifically. It was planned that bivariate correlations would be performed to examine overall relations between the reasons for analgesic use factors and participant functioning and that these would be followed by linear regression analyses to determine aspects of shared and unique variance accounted for by the factors after controlling for relevant demographic and pain-related variables.
METHODS

Sampling Procedures
Participants were recruited from Amazon Mechanical Turk (MTurk), an online method of collecting survey data from a national pool. The MTurk system is secure and allows for participant confidentiality, as researchers only have access to an MTurk "worker ID" that is not linked to any protected health information. Participants who completed the survey were paid $3.00 for their time. This study was approved by the University of New Mexico's Human Subjects Institutional Review Board.
Potential participants initially completed an unpaid screening survey that was used to evaluate study inclusion criteria. To be eligible for the study, participants had to report that they experienced pain: (1) on most days of the week (ie, ≥ 4 d/wk), (2) at an average weekly intensity of ≥ 3 on an 11-point numerical rating scale (NRS), and (3) for at least 3 months in duration. Individuals who did not meet each of these 3 criteria were not eligible, or were individuals who experienced only chronic headache pain. In total, 420 individuals met these initial inclusion criteria and began the survey. Of these, 403 (95.6%) provided usable data. For the 17 individuals who provided unusable data, responses were either missing entirely (n = 10) or limited to demographic information only (n = 7).
Participant Characteristics
Participants with usable data were asked to list all overthe-counter and prescribed medications that they were currently taking for chronic pain, including daily dosage. This list was reviewed for each participant by the first author (K.E.V.) and coded to identify individuals who reported taking any analgesic and to identify those who reported taking any opioid medications. For the present analyses, data were used from the 334 participants who met study inclusion criteria and who also reported taking at least 1 analgesic medication for the treatment of chronic pain. Within this sample, the average number of analgesics being taken was 1.5 (SD = 0.85; range, 1 to 6). Of these, 131 (39.2%) reported taking opioid medication. Additional analgesics that were reported included: nonsteroidal antiinflammatories (n = 187; 56.0%), acetaminophen (n = 54; 16.2%), muscle relaxants (n = 44; 13.2%), anticonvulsives (n = 43; 12.9%), selective serotonin or norepinephrine reuptake inhibitors (n = 37; 11.1%), benzodiazepines (n = 15; 4.5%), and tricyclic antidepressants (n = 5; 1.5%).
In terms of demographic information, most participants were female, 54.5%, with an average age of 36.6 years (SD = 11.6; range, 19 to 73). The majority identified themselves as of white, non-Hispanic ethnicity (76.4%; Asian: 8.0%; Hispanic: 6.5%; black: 6.2%; Native American: 1.2%; Middle Eastern: 0.6%; Other: 1.1%) and were married or cohabitating with a partner (56.5%; single: 33.9%; divorced: 8.3%; widowed: 1.3%). They averaged 16.6 (SD = 2.5) years of education with most reporting completion of a Bachelor's degree (34.9%; some university: 34.3%; postgraduate degree: 15.4%; technical/ trade school degree: 8.6%; high school degree: 6.5%; did not complete high school degree: 0.3%). Over half were employed on a full-time (37.2%) or part-time (23.2%) basis. These employed individuals reported missing an average of 2.9 days of work (SD = 5.8) due to pain over the preceding 3 months. For those who were not working, 39.6%, unemployment duration averaged 3.4 years (SD = 3.7).
Pain duration averaged 7.0 years (SD = 6.6; median: 5.0; range, 3 mo to 39 y). The most frequently reported pain site was low back (52.6%), followed by lower extremity (12.1%), neck/head (11.5%), full body (11.2%), upper extremity (6.3%), pelvis/hips (4.2%), mid-back (1.2%), and other (eg, abdominal; 0.9%). Secondary pain sites were noted by 95 individuals (28.4%).
Measures
Item Pool-Reasons for Analgesic Use Measure (RAUM)
A pool of potential items was initially written by the first author (K.E.V.), a clinical psychologist with over 15 years of experience in the assessment and treatment of chronic pain. During this initial stage of development, items were generated across 7 broad content areas, which included taking analgesics for: (1) pain relief (eg, "to help reduce my pain"); (2) functional improvement (eg, "so I can do more activities"); (3) decreased distress (eg, "because they help me feel better emotionally"); (4) decreased stress/anxiety (eg, "so I can relax"); (5) sedation (eg, "to help me fall asleep"); (6) compliance with prescription/provider instructions (eg, "because they have been prescribed for me"); and (7) reducing feelings of helplessness/feeling as if one was doing something (eg, "because I don't know what else to do"). These were conceptual domains used to aid in the generation of specific items and were not assumed be predictive of eventual factor structure.
Items were rated on a 5-point Likert-type scale as follows: 0: strongly disagree, 1: disagree, 2: neither agree nor disagree, 3: agree, 4: strongly agree. As all items were scored in the same direction, with higher numbers indicating stronger endorsement of the content of each item, we planned to use a simple sum of items to calculate subscale or total scores for the measure.
Following the generation of the item pool, 3 experts with experience in measure construction and chronic pain were asked to consider the items and provide evaluation and feedback. On the basis of the suggestions of this group of reviewers, a final pool of items was constructed by the study authors and was called the RAUM. Disagreements on the wording of items were resolved via consensus and it was agreed that no items would be deleted from the item pool as initial data collection would aid in the identification of problematic items. These items are listed in Supplementary Table 1 (Supplemental Digital Content 1, http://links.lww.com/CJP/A508).
Measures of Participant Function
Several measures of functioning were included in the questionnaire battery to evaluate aspects of convergent and divergent validity in the RAUM. These measures were selected based on expected relations with scores on the RAUM, as well as their relevance to patient functioning.
Average pain intensity and pain-related distress over the preceding week were assessed separately using 2 NRS. Each NRS ranged from 0 (no pain/pain-related distress) to 10 (maximal pain/pain-related distress possible).
Depressive symptoms over the preceding 2 weeks were evaluated using the 16 item British Columbia Major Depression Inventory (BCMDI 21 ). Possible scores range from 0 to 80, with higher scores indicating more severe symptoms. Previous studies in chronic pain have provided support for the BCMDI's internal consistency, as well as aspects of convergent validity and responsiveness to intervention. [22] [23] [24] [25] In the present sample, the internal consistency of the BCMDI was acceptable (Cronbach's α = 0.90).
Given hypotheses that reasons for pain medication use would be associated with risk of problematic substance use, 2 measures of substance use were included. First, the Current Opioid Misuse Measure (COMM 26 ) was used to evaluate potential for concurrent risky opioid use. The COMM is a 17-item measure of risk for problematic opioid use and evaluates behavior relevant to analgesic use over the preceding 30 days. It includes a mix of items that ask directly about analgesic use (eg, "How often have you been worried about how you're handling your medications?"), as well as items that ask about other relevant aspects of functioning (eg, "How often have you been in an argument?"; "How often have you had trouble with thinking clearly or had memory problems?"). The items of the COMM assess the frequency of behavior on a 0 to 4 scale, with total scores ranging from 0 to 68 and higher scores indicating greater risk of current opioid misuse. In the present sample, internal consistency was acceptable (Cronbach's α = 0.88). Scores on the COMM were used in correlation and regression analyses for both the larger sample and the subsample using opioids. While the COMM has not previously been used in individuals not taking opioids, its item content is relevant to analgesic consumption more broadly and thus we anticipated that COMM scores would potentially be relevant in examining how reasons for analgesic use related to risky analgesic consumption.
We also assessed alcohol use patterns given data that opioid and alcohol co-use is relatively common and is associated with substantial risk of morbidity and mortality, 27 as well as the fact that the experience of pain increases the probability of relapse to alcohol use in those treated for alcohol use disorder. 28, 29 Alcohol use was assessed using the 10-item Alcohol Use Disorders Identification Test (AUDIT 30 ). Items range from 0 to 4 and are summed to yield a total score that ranges from 0 to 40 with higher scores indicating greater probability of risky alcohol use. The AUDIT has been widely used to assess for problematic drinking with strong evidence of diagnostic accuracy across a variety of clinical and nonclinical samples. 31, 32 The AUDIT's internal consistency in the present sample was acceptable (Cronbach's α = 0.89).
Analytic Approach
Initially, to identify potentially problematic items, each of the 34 items in the RAUM item pool was examined to identify extreme skewness, kurtosis, or limited variability. Consistent with extant guidance on normal univariate distribution, 33 items with skewness or kurtosis values in excess of 2 were eliminated. Next, item-total correlations were calculated to identify items that did not correlate appropriately with the measure's total score.
Following the removal of problematic items, exploratory factor analyses (EFA) were performed to identify cross-factor or low-factor loading items and identify an initial factor structure. A Geomin rotation was used, which allows items and factors to correlate. The determination of the final factor structure was based on a number of considerations, including overall model fit, comparative fit across different factor solutions, scree plot, Eigenvalues, parsimony, and interpretability. Overall and comparative model fit was primarily evaluated using the Root Mean Square Error of Approximation (RMSEA), Standardized Root Mean Squared Residual (SRMR), and the Comparative Fit Index (CFI). Established guidelines suggest that good fit is indicated by RMSEA values of 0.05 and lower (with values below 0.10 indicating modest fit), SRMR values of 0.08 and lower, and CFI values of 0.95 and higher. 34, 35 In addition, a 90% confidence interval (CI) was calculated for RMSEA to test for "close" model fit, where a significant finding indicates model fit is worse than close. The appropriateness of different factor solutions was evaluated by assessing whether model fit improved with the addition of 1 more factor, as indicated by a significant χ 2 value. The EFA process was iterative in nature, where potentially problematic items were identified and removed and the analyses repeated until a stable and psychometrically sound factor structure was identified for the RAUM. The EFA process was initially performed in the entire sample of individuals taking analgesics (N = 334). Once a stable factor structure was identified, this structure was then evaluated in the subsample taking opioids (N = 131). All analyses used Mplus version 7.4. 36 Once a final factor structure was identified, the psychometric characteristics and utility of the factors was assessed. Internal consistency coefficients were calculated, and the relations among the RAUM factors and other measured variables were evaluated using correlation and multiple linear regression methods. In the regression analyses, sex, age, years of education, pain duration, and usual pain intensity were controlled for statistically. Consistent with the EFA analyses, 2 sets of correlations and regressions were performed, one for the entire sample taking analgesics and the other for the sample taking opioids. For the final set of 21 items, a 3-factor solution continued to appear to be the most appropriate factor solution. Each of the 3 factors had an Eigenvalue of > 1 (ie, 7.4, 3.7, 2.0), all primary factor loadings exceeded 0.39 and no cross-loading exceeded 0.17. See Table 1 for rotated factor loadings. The χ Evaluation of the items within each factor indicated that item content was both interpretable and logical. The first factor was comprised of items indicating that respondents were taking analgesics for the purposes of pain reduction and functional improvement (eg, "To help reduce pain"; "So I can do more activities"). This factor was therefore labeled as pain/ function. The second factor was comprised of items indicating that analgesics were being taken for the purposes of emotional modulation or sedation (eg, "Because they help me feel better emotionally"; "To help me fall asleep."). This factor was labeled as mood/sedation. The final factor included items indicating that compliance with prescribed instructions was a reason for analgesic consumption. This factor was therefore labeled as compliance. Descriptive data for these 3 subscales and the other measures of functioning are included in Table 2 for the total sample and the subsample of opioid users. We have also included descriptive information on the RAUM and other functional measures for the nonopioid users to provide more complete details of sample characteristics. As noted in that table, internal consistency for all 3 factors was acceptable, ranging from 0.83 for the pain/function subscale to 0.94 for the mood/sedation scale.
Supplementary
Following this initial evaluation of factor structure for the full sample, the fit for a 3-factor solution was examined using data from the subsample that were using opioids. Fit was adequate in the subsample, and values were similar to those observed in the full sample (RMSEA: 0.06 [90% CI, 0.05-0.08], P "close fit" = 0.11, SRMR: 0.04, TLI: 0.95). All items loaded onto the same factors as they had in the analyses using the full sample. Internal consistency for all 3 factors remained robust, ranging from 0.78 for the pain/ function subscale to 0.93 for the mood/sedation scale. The final version of the RAUM, including items for both the Pain/Function and Mood/Sedation subscales, and scoring instructions is located in Appendix A (Supplemental Digital Content 2, http://links.lww.com/CJP/A513).
Correlation and Regression Analyses
Correlations among the 3 RAUM subscales and the measures of pain intensity, pain-related distress, depression, and substance use were performed next for both the full sample and the opioid-using sample. Results of these analyses are displayed in Tables 3 and 4 , for the full sample and opioid-using sample, respectively. Because of the large number of correlations, only those that were significant at P < 0.01 were interpreted.
Overall, RAUM factor scores were significantly correlated with one another (range r = 0.21 to 0.39, all Ps < 0.01). Further, across both full and subsample, the mood/sedation factor was significantly correlated with all measures of functioning, with the sole exception of pain intensity. In each case where a significant correlation was indicated, the directions were all positive, indicating that as the strength of endorsement of these purposes for analgesic use increased, there were related increases in reported levels of pain-related distress, depression, opioid misuse, and alcohol misuse.
The pain/function factor had smaller and less robust relations with these same measures, and was significant only for pain-related distress and depression for the full sample (r = 0.16 and 0.17, respectively, both Ps < 0.01). Although the magnitude of these correlations was modest, the positive direction of the relation is interesting-stronger endorsement of using analgesics for pain reduction or functioning improvement was related to greater levels of reported painrelated distress and depression. Finally, the compliance factor was not significantly correlated with any measure of pain or functioning in either the full or subsample. Given this pattern of correlations, the compliance subscale was not investigated further in regression analyses.
As the final analytic step, linear regression analyses were performed to examine unique variance accounted for by the 2 remaining RAUM factors, after controlling for demographic and pain-related factors. The results of these analyses are displayed in Table 5 , with the full sample results displayed in the left-hand column and the subsample of opioid-using patients displayed in the right-hand column. The overall pattern of results closely mirrored those of the bivariate correlations.
For the full sample, the RAUM factors did not account for significant variance in pain intensity, nor were β values significant. In all other regressions, however, the scales did account for significant unique variance after controlling for demographic and pain-related variables (range r 2 = 0. For the opioid-using sample, an almost identical pattern of findings was present. The only difference was for alcohol misuse, where the RAUM factors did not account for significant variance (r 2 = 0.02, P = 0.21). For the 3 remaining variables of pain distress, depression, and opioid misuse, the variance accounted for by the RAUM factors was significant, although values were smaller than when the full sample was investigated (range r 2 = 0.11 [depression; opioid misuse] to 0.21 [pain distress], all Ps < 0.01). In each case, the β for the mood/sedation factor was significant, whereas it was nonsignificant for the pain/function factor. Usual pain and pain distress over the past week measured using a 0 to 10 Numerical Rating Scale; depression measured using the British Columbia Major Depression Inventory; opioid misuse measured using the Current Opioid Misuse Measure; alcohol misuse measured using the Alcohol Use Disorders Identification Test. *Cronbach's α. RAUM indicates Reasons for Analgesic Use Measure. 
DISCUSSION
The primary aim of the present study was to examine why individuals with chronic pain were taking analgesics and whether these reasons were meaningfully associated with relevant aspects of functioning and substance use patterns. The results of the factor analysis identified a total of 3 primary reasons, which included use to: (1) reduce pain and improve function; (2) achieve emotional modulation and sedation; and (3) adhere to provider instructions. The overall results suggest that there may be a particular risk present when one uses analgesics for the second of these reasons. That is, using analgesics for the purposes of emotional modulation or for sedation was strongly associated with greater pain-related distress and depression, as well as increased risk of problematic opioid and alcohol use in the full sample. This pattern was almost identical for the subset that were using opioids, with the sole exception of risk of alcohol misuse, for which the relation was nonsignificant.
It is important to note that these are cross-sectional results, thus the causal direction of relations among the measured variables cannot be surmised. It is likely that the observed relations are bidirectional in nature. Nonetheless, these data do suggest that the use of analgesics for the purposes of emotional modulation or sedation may represent a clinically significant marker for potential problems, in that scores on the RAUM mood/sedation subscale were reliably associated with greater problems. Thus, even bearing in mind the cross-sectional nature of these data, it seems plausible that the use of the RAUM in individuals taking analgesics for chronic pain may provide a clinically useful screen for the presence of potential problems in other domains.
The other primary reasons for analgesic use identified, including their use for pain reduction and functional improvement or for the sake of adhering to provider orders, were not reliably related to pain intensity, emotional functioning, and risk of substance misuse. It may be that these represent relatively "benign" purposes for analgesic consumption in that they are not associated with significant distress, depression, or risk of opioid or alcohol misuse. That being said, it is curious that greater use of analgesics for their intended purposes of pain reduction and functional improvement was not associated to less pain, pain-related distress, depression, or risk of substance misuse. In fact, in the full sample, greater use of analgesics for this purpose was moderately associated with increases in pain-related distress and depression. If these results are replicated, it will be worth considering why greater endorsement of analgesic use for their intended purpose is not associated with less pain and greater functioning, as common sense would suggest that it ought to be.
From a measure development perspective, these data provide initial support for the RAUM. The 3-factor structure appeared statistically robust and internal consistency values were good. These analyses also provide evidence of the RAUM's discriminant validity, in that only the mood/ sedation subscale was reliably and positively related to the other measures used. In contrast, the pain/function subscale tended to have small, nonsignificant relations with these same measures, with the sole exceptions of modest significantly positive correlations with pain-related distress and depression in the full sample only. In a similar vein, the compliance subscale was not related to any of the other measures analyzed. It may be that these latter 2 factors are not all that relevant with aspects of functioning, but it seems appropriate to examine the performance of the RAUM subscales in additional samples to determine the overall relevance and utility in pain settings before making firm conclusions.
In addition to these primary implications, it is worth commenting upon the use of the COMM in this sample of individuals with chronic pain. As noted in the introductory portions of this paper, the COMM has not, to our knowledge, been examined within samples of nonopioid-using individuals with chronic pain. It is interesting that the pattern of findings observed in the COMM validation studies, where COMM scores are positively correlated with problems in functioning, were also observed in this sample of individuals reporting use of any analgesic for chronic pain. Given that the COMM includes several items assessing the experience of difficult emotions (eg, anger), it may be that it is also useful in samples who are taking analgesics in addition to opioids.
The strength with which we can draw conclusions from the present results is limited in several ways. First, participants self-reported the presence of chronic pain in an online survey and were not evaluated at any point in this study by health care personnel. Although our screening measure for the presence of chronic pain assessed pain frequency, intensity, and duration, and is generally consistent with recommended criterion sets for chronic pain, further work is necessary to examine the potential utility of the RAUM, particularly in relation to specifically validating the measure in samples presenting for assessment or treatment of chronic pain. Further, future work may benefit from the inclusion of a formal assessment of respondent compliance with prescribed instructions for analgesic use, as well as an assessment of the item's susceptibility to social desirability. Second, the generation of the RAUM items did not include input from people with chronic pain and thus some key reasons for analgesic use may have been omitted. In addition, analgesic use was also self-reported and it is possible that all analgesics were not recorded by participants or that there was inaccuracy in reporting. Furthermore, while we did specifically examine data in individuals who reported consuming prescribed opioids for the treatment of chronic pain, the sample size was modest, and examination of the utility of the RAUM in a larger opioid-using sample seems necessary. Descriptively, the overall sample was somewhat younger in age (average age of 36.6) than the typical age of patients presenting for pain treatment, which tends to be mid to late 40s or later in many samples. 1,37,38 Finally, as Usual pain and pain distress over the past week measured using a 0 to10 Numerical Rating Scale; depression measured using the British Columbia Major Depression Inventory; current opioid use measured using the Current Opioid Misuse Measure; current alcohol misuse measured using the Alcohol Use Disorders Identification Test.
RAUM indicates Reasons for Analgesic Use Measure. +P ≤ 0.10. *P ≤ 0.05. **P ≤ 0.01. ***P ≤ 0.001.
noted, all data were collected at a single point of time. Thus, it is not possible to make directional attributions among the relations that were observed here. For example, it is not clear if using analgesics for the purposes of emotional modulation contributes to greater depression or if the relation occurs primarily in the opposite direction. Given these limitations, potential clinical implications are largely hypothetical. If further study supports the utility of the RAUM and indicates that using analgesics for the purposes of emotional modulation or sedation is reliably related to poorer functioning, then it will be important to determine methods to disrupt this influence. For example, for some individuals, it may be that education surrounding appropriate and inappropriate analgesic consumption is sufficient to decrease use for these problematic purposes. For others, more intensive behavior change interventions, or perhaps more frequent monitoring of analgesic consumption, may be required to address the emotional disruptions more directly or aid in sleep difficulties. If the RAUM can identify those using analgesics for problematic purposes, then it may open the door for corrective intervention.
